ERBB2 and breast carcinoma: In this regard, Kondo et al. have recently reported generation and evaluation of the 225Ac-labeled trastuzumab IgG, F(ab’)2 and Fab for theranostic SPECT/CT imaging and alpha-particle radioimmunotherapy of HER2-positive human breast cancer [11].